| | Advanced Search

 

John Perilli: Peter Neronha, US Attorney & Rising Political Star?—He could be tough to beat...

Michael Riley: Rhode Island’s Potential Pension Nightmare—Headed for disaster...

Rob Horowitz: The Civil Rights Act, 50 Years Later—Celebrating a milestone...

Fund for Community Progress Honors GoLocalProv + Other RI Leaders—Recognizing outstanding contributions to the RI community

Organize + Energize: 7 Reasons to Hire a Professional Organizer—With a little help from your friends...

International String Trio to Perform at Pot au Feu in Providence—A fabulous evening of music, food and wine

RE/MAX Reports 1.3% Increase in Pending RI Home Sales for March—Increase in pending sales, but decrease in home…

Former URI Basketball Player Arrested on Murder Charge—Former URI Basketball Player Arrested on Murder Charges

NEW: Rhode Island Named 6th Best State to Eat Local—One of the nation's best in availability of…

NEW: Providence Attorney Nicholas Hemond Joins DarrowEverett LLP—Will serve as new litigation associate

 
 

Smart Benefits: Calmar Cancels Out Pain

Monday, December 02, 2013

 

Calmar is the only Medical Treatment Center in the US treating severe, chronic, neuropathic and oncologic pain patients exclusively using the MC-5A, an advanced new computerized medical device.

Many people with chronic pain try various therapies, narcotics, or surgeries to get relief – often without success.

Now, there's a new approach from Calmar Pain Relief, LLC in West Warwick, Rhode Island, that has an 80 percent success rate with patients. And people from all over the world are traveling here in droves to try it.

The Message? No Pain

Calmar is the only medical treatment center in the United States that treats severe, chronic, neuropathic and oncologic pain patients exclusively with the MC-5A, a new computerized medical device.

The device relies on Scrambler Technology (“ST”) that uses surface electrodes on the skin (similar to an EKG) to transmit synthetic non-pain information through nerve receptors in the area of the patient's pain. The perception of pain is cancelled when the no-pain message replaces that of pain, and the patient experiences a quick and significant reduction of pain.

Lasting Results

The treatment involves a series of up to ten treatments over a two-week period. Relief can last several months to a year, and in some cases, permanently. The therapy can also be repeated, if needed.

International Adoption

The MC-5A technology was developed from the research of Professor Giuseppe Marineo, founder and manager of Delta Research and Development, which is affiliated with Tor Vergata University of Rome, Italy. On February 19, 2013, the United States Patent and Trademark Office issued an International Patent for Scrambler Therapy. Scrambler Therapy is also patented in Italy.

Local Experience

Calmar is managed by Dr. Stephen D’Amato, who studied in Italy under Professor Giuseppe Marineo and is the most experienced doctor in the United States using this technology. Besides serving as Medical Director at Calmar, he trains physicians from nationally reknown facilities like the MAYO Clinic in Minnesota and the University of Miami as well as those affiliated with Harvard Medical School.

Hospitals from all over the world who know of Dr. D’Amato and send their worst-case patients to him for help.

Calmar Candidates...and Coverage

Calmar’s pain therapy is available to patients who suffer from complex regional pain syndrome, failed back surgery syndrome, neuropathy of the legs and feet, chemotherapy induced peripheral neuropathy, sciatic and lumber pain, fibromyalgia, and several type of other medical conditions

Insurance carriers are slowly starting to embrace Calmar’s approach, with UnitedHealthcare the first carrier locally to pay for this treatment within their plans.

Expanding Relief

Following the success in Rhode Island, Calmar has plans to expand into other markets with centers planned soon for Massachusetts and Florida.

Calmar is the only Medical Treatment Center in the US treating severe, chronic, neuropathic and oncologic pain patients exclusively using the MC-5A, an advanced new computerized medical device.

Amy Gallagher has over 21 years of healthcare industry experience guiding employers and employees. As Vice President at Cornerstone Group, she advises large employers on all aspects of healthcare reform, benefit solutions, cost-containment strategies and results-driven wellness programs. Amy speaks regularly on a variety of healthcare-related topics, and is often quoted by national publications on the subject matter. Locally, Amy is a member of SHRM-RI, the Rhode Island Business Group on Health, and the Rhode Island Business Healthcare Advisory Council.

 

Related Articles

 

Enjoy this post? Share it with others.

Comments:

lonzo oscar

I think you made a mistake when you said, "...UnitedHealthcare the first carrier locally to pay for this treatment within their plans.."

Per UHC's most recent medical policy release (12/2013):

"Unless an NCD, LCD or coverage article is published to address coverage for a specified Category III CPT code, UHC considers all services and procedures listed in the current and future Category III CPT code list as not proven effective and will deny submitted claims as not medically necessary."

The policy statement identifies "scrambler technology" as possessing a category III code. There is NO other mention of the device -- i.e. no other article addresses coverage. Hence, it is NOT covered.

In fact, I could fond NO medical policy statement from ANY third party reimburser indicating the device was anything other than "experimental" and not covered.




Write your comment...

You must be logged in to post comments.